
AQST Stock Forecast & Price Target
AQST Analyst Ratings
Bulls say
Aquestive Therapeutics Inc is poised for positive growth due to its strong positioning in the no-needle epinephrine market, enhanced by the opportunity for both oral and intranasal alternatives. The FDA's recent decision not to require an Advisory Committee meeting for the NDA of Anaphylm has led to a significant 43.77% increase in shares, reflecting investor confidence in the company's product pipeline. Furthermore, the successful submission of a comprehensive data package addressing key regulatory topics suggests a favorable trajectory for potential approval and market expansion.
Bears say
Aquestive Therapeutics faces several fundamental issues contributing to a negative outlook on its stock. The company is at risk of unsuccessful development of its pipeline product AQST-109, coupled with potential revenue erosion from its licensed commercial products, which could adversely affect its financial performance. Additionally, the need for capital raise to strengthen the balance sheet raises concerns about its liquidity and long-term viability in a competitive market.
This aggregate rating is based on analysts' research of Aquestive Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
AQST Analyst Forecast & Price Prediction
Start investing in AQST
Order type
Buy in
Order amount
Est. shares
0 shares